Antibe Therapeutics

Antibe Therapeutics is a publicly traded biotechnology company focused on the design and development of novel drugs targeting diseases characterized by inflammation, pain, and/or vascular dysfunction. Antibe Therapeutics' drug sales channels are aimed at major markets for non-addictive treatments of chronic and post-surgical pain. The company's lead drug is currently in the late stages of Phase II trials, demonstrating unprecedented safety in treating chronic pain, a condition affecting over 50 million Americans alone. Antibe Therapeutics' second pipeline drug aims to replace various opioids, addressing a widespread and urgent public health issue. The company's third drug is a daily safe aspirin — offering anti-stroke and anti-cancer benefits without compromising the gastrointestinal tract.